New Therapy Approved for Relapsed Leukemia
FDA approves Revuforj® for acute leukemia with KMT2A translocation, offering a new hope for patients.
The FDA has approved Revuforj® (revumenib) as the first menin inhibitor for relapsed or refractory acute leukemia with KMT2A translocation, applicable to patients aged one year and older. This breakthrough therapy demonstrated a 21% complete remission rate in the Phase 1/2 AUGMENT-101 trial, with median remission duration of 6.4 months and manageable safety outcomes. The approval provides a critical option for this aggressive leukemia subtype, marked by high relapse rates and poor survival outcomes.
Syndax plans a November U.S. launch for adult and pediatric doses, with expanded pediatric formulations expected in 2025.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Altro da Pharma News
Tutti gli articoli →
Curia New York riceve una lettera di richiamo (Warning Letter) dalla FDA per migliaia di iniezioni cromatografiche non documentate
Ab Science rivede i tempi dei trial dopo tre ispezioni GCP
Discussion